Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT03072147·Phase 2·INTERVENTIONAL

Teriparatide as a Chondroregenerative Therapy in OA

TeriparatideInflammationCompleted

Status

Completed

Phase

Phase 2

Enrollment

76

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this study is to evaluate teriparatide (TP) as a chondroregenerative therapy for human knee osteoarthritis (OA). The central hypothesis to be tested is that TP supports structural modification of the joint and improves biomarker, functional and patient-reported measures of knee OA.

Full detailed description

This is a prospective, randomized, placebo controlled, double blinded, crossover study. The investigators will identify, recruit and enroll 80 subjects with symptomatic, unilateral medial compartment knee OA. Enrolled subjects will be randomized into equal TP (in the FDA approved form, Forteo) or placebo arms of 40 subjects each (includes allowance for a 25% dropout rate with no replacements). All subjects will be treated for 24 weeks, then followed for an additional 24 weeks to assess the durability of any observed effects. The trial incorporates a crossover design, based on interim analysis of the 24 week outcome data after every subject has completed the 24 week treatment period. If positive effects on structural and/or biomarker measures are apparent from the interim analysis, placebo treated subjects will be offered TP (in the FDA approved form, Forteo) and followed for an additional 24 weeks. If the placebo subjects who choose to participate in the crossover treatment have not yet completed the 48 week visit, it will not occur. These subjects will begin the crossover portion 24 week treatment and monitoring period when they receive the TP pens (in the FDA approved form, Forteo).

Interventions

Treatment arms and agents.

DRUG

Teriparatide

20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.

DRUG

Placebo

20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.

Timeline

From registration to results.

  1. First posted

    Mar 7, 2017

  2. Study start

    May 1, 2017

  3. Primary completion

    Sep 30, 2022

  4. Study completion

    Sep 30, 2022

  5. Results posted

    Not reported

  6. Registry updated

    May 12, 2023

Outcomes

What the study measures.

Primary outcomes

Knee MRI

Time frame · Change from Baseline through study completion (baseline, 24 weeks, 48 weeks), an average of one year.

Analysis using Regional Cartilage Volume Segmentation

Secondary outcomes

Flexed Knee Radiograph

Time frame · Change from Baseline through study completion (baseline, 24 weeks, 48 weeks), an average of one year.

Interpreted using fractal signature analysis.

Urine Biomarker Analysis

Time frame · Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year.

Analyzed immediately via enzyme-linked immunosorbent assay (ELISA) to quantify the following biomarker: urinary type II collagen

Serum Biomarker Analysis

Time frame · Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year.

Analyzed immediately via enzyme-linked immunosorbent assay (ELISA) to quantify the following biomarker: serum type II collagen degradation neoepitope.

GAITRite

Time frame · Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year.

Change in gait pre- and post-treatment analyzed using the GAITRite walking test.

Timed up and go

Time frame · Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year.

Change in gait pre- and post-treatment analyzed using the timed-up-and-go (TUG) test.

WOMAC 3.1

Time frame · Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year.

The Western Ontario and McMaster Universities Arthritis Index (WOMAC 3.1) measures pre- and post-treatment changes in subjective pain and functionality.

PROMIS Depression

Time frame · Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year.

The Depression scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures measures subjective changes in mood, pre- and post-treatment.

PROMIS Pain Interference

Time frame · Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year.

The Pain Interference scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures subjective changes in pain distress, pre- and post-treatment.

PROMIS Physical Function

Time frame · Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year.

Physical function scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures subjective changes in mobility and activities of daily living, pre- and post-treatment.

Eligibility

Who can take part.

Minimum age
40 Years
Maximum age
60 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: 1. male or female 40 to 60 years old. 2. radiographic evidence of Kellgren-Lawrence score (K-L score) grade I-II OA in the affected knee 3. unilateral symptomatic knee OA 4. willingness to forgo potential standard of care treatments (hyaluronic acid and cortisol injections) for knee pain for the duration of the study 5. body Mass Index of ≤40 6. normal screening vitamin D levels (≥20 and ≤100 mg/ml) 7. normal screening serum calcium level (8.5- 10.2 mg/dL) 8. a negative screening serum pregnancy test for premenopausal women Exclusion Criteria: 1. history of primary hyperparathyroidism disease, hypercalcemia, or persistently abnormal intake PTH levels (≥10 or ≤65 pg/ml) 2. history of musculoskeletal malignancy or solid organ carcinoma 3. active renal disease defined by a creatinine clearance of \<35 or history of kidney stones within the past year 4. use of anticonvulsant or digoxin therapy 5. inflammatory disease (bowel disease, spondylitis, lupus, fibromyalgia, psoriasis, rheumatoid arthritis, etc) 6. current or past treatment with teriparatide 7. use of immunosuppressants 8. severe claustrophobia, retained eye or skull metal fragments, metal hardware in or around the affected knee or other standard contraindications to MRI (cochlear implants, pacemakers) 9. dementia, cognitive impairment or other factors that referring provider feels would prevent ability to obtain informed consent and/or follow study protocol 10. pregnancy or intent to become pregnant in the two and a half years following enrollment 11. women who are currently breastfeeding 12. Paget's disease 13. osteoporosis diagnosis by DXA in medical history (T-score less than or equal to -2.5) 14. reliance on assistive walking devices (canes, walkers, braces, etc.) 15. participation in concurrent clinical studies involving investigational medications

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

URMC Orthopaedics, Clinton Crossings Building D

Rochester, New York, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Teriparatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsTeriparatide trial dashboard →DatabaseTeriparatide database entry →ResearchTeriparatide research guide →